HER2 status predicts for upfront AI benefit: a TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2

- Bartlett, John M. S., Ahmed, Ikhlaaq, Brookes, Cassandra L., Forbes, John F., Viale, Giuseppe, Cuzick, Jack, Dowsett, Mitchell, Rea, Daniel W., Regan, Meredith M., Sestak, Ivana, Mallon, Elizabeth A., Dell'Orto, Patrizia, Thürlimann, Beat, Seynaeve, Caroline, Putter, Hein, Van de Velde, Cornelis J. H.

Predictive algorithms for adjuvant therapy: transATAC

- Dowsett, Mitch, Salter, Janine, Zabaglo, Lila, Mallon, Elizabeth, Howell, Antony, Buzdar, Aman U., Forbes, John, Pineda, S., Cuzick, Jack

Which patients benefit most from adjuvant aromatase inhibitors?: results using a composite measure of prognostic risk in the BIG 1-98 randomized trial

- Viale, G., Regan, M. M., Lang, I., Thürlimann, B., Mouridsen, H., Mauriac, L., Gelber, R. D., Price, K. N., Goldhirsch, A., Gusterson, B. A., Coates, A. S., Dell'Orto, P., Mastropasqua, M. G., Maiorano, E., Rasmussen, B. B., MacGrogan, G., Forbes, J. F., Paridaens, R. J., Colleoni, M.

Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results

- Coleman, R., de Boer, R., Frassoldati, A., Campbell, I., Paija, O., Martin, N., Modi, A., Bundred, N., Eidtmann, H., Llombart, A., Davidson, N., Neven, P., von Minckwitz, G., Sleeboom, H. P., Forbes, J., Barrios, C.

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial

- Rabaglio, M., Sun, Z., Colleoni, M., Pienkowski, T., Nogaret, J. -M., Láng, I., Smith, I., Gelber, R. D., Goldhirsch, A., Coates, A. S., Price, K. N., Castiglione-Gertsch, M., Hawle, H., Thürlimann, B., Mouridsen, H., Campone, M., Forbes, J. F., Paridaens, R. J.

Mammographic (breast) density as a potential biomarker for endocrine trial treatment efficacy in breast cancer prevention

- Jobling, Judith Marie

Symptoms of endocrine treatment and outcome in the BIG 1-98 study

- Huober, J., Cole, B. F., Smith, I., Wardley, A., Price, K. N., Goldhirsch, A., Coates, A. S., Colleoni, M., Gelber, R. D., Thürlimann, B., Rabaglio, M., Giobbie-Hurder, A., Wu, J., Ejlertsen, B., Bonnefoi, H., Forbes, J. F., Neven, P., Láng, I.

Aromatase inhibitor induced musculoskeletal syndrome: a significant problem with limited treatment options

- Lombard, Janine M., Zdenkowski, Nicholas, Wells, Kathy, Beckmore, Corinna, Reaby, Linda, Forbes, John F., Chirgwin, Jacquie